CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

By R. Marcus, K. Imrie, A. Belch, D. Cunningham, E. Flores, J. Catalano, P. Solal-Céligny, F. Offner, J. Walewski, J. Raposo and 2 more. Blood, 2005

1,000 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/2bbd8b1c0d7bd429ead534e9a57c0879b27716d7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. P. Feugier
2. A. Hoof
3. C. Gisselbrecht
4. R. Bouabdallah
5. B. Christian
6. F. Morschhauser
7. F. Reyes
8. A. Bosly

Citations in the corpus

• Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. (2014, neutral): “Hyperglycemia 0 2 (2) 1 (,1) 5 (4) Back pain 0 1 (1) 0 4 (3)”
• Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. (2005, result): “Other studies have been conducted in patients with follicular lymphoma or mantle-cell lymphoma and showed the same benefit for the combination of rituximab plus chemotherapy.(19,20) These data represent a real breakthrough in the treatment of lymphoma patients and suggest that R-CHOP should become t”
• Follicular lymphoma international prognostic index (2006, background): “Two main chemotherapy regimens have been proposed: CVP [ 14 ] or the conventional CHOP [15].”